BioCentury | Feb 18, 2021
Management Tracks

Day One names York COO, CFO; plus moves at Coherus, Antios, ArsenalBio, Affinia, Artelo and more

After raising a $130 million series B round last week, pediatric oncology company Day One Biopharmaceuticals LLC hired Charles N. York II as COO and CFO. York was CFO and head of corporate development at...
BioCentury | Feb 12, 2021
Emerging Company Profile

With $70M A round, Takeda deal, 5AM’s Ensoma aims for accessible cell and gene therapies via empty adenoviral vectors

Launched with a $70 million series A round and a Takeda deal in hand, Ensoma is the latest company focused on broadening access to cell and gene therapies, leveraging high-capacity vectors to  develop one-time, off-the-shelf...
BioCentury | Jan 20, 2021
Finance

Rexgenero rebrands as Ikaxa, raises £40M following gene therapy deal

With an aim to bring its recently acquired synthetic gene delivery platform into the clinic, Rexgenero Ltd. has recapitalized and rebranded as cell and gene therapy company Ikaxa Ltd. The London-based biotech said undisclosed existing...
BioCentury | Jan 20, 2021
Emerging Company Profile

Aulos: Tackling the IL-2 space with computational biology

Apple Tree Partners launched Aulos into the crowded IL-2 space last week with a $40 million series A round and a computationally designed IL-2-binding antibody it thinks could have an edge in efficacy...
BioCentury | Jan 13, 2021
Deals

Boehringer accesses untouched cancer targets through Enara deal

Boehringer’s reach into the most cutting-edge science continues through its new deal with Enara to access dark antigen targets for cancer immunotherapies.  Boehringer Ingelheim GmbH teamed up with...
BioCentury | Jan 13, 2021
Product Development

Why Verve chose base editing over standard CRISPR for its lead CV candidate

Verve’s non-human primate data makes the case that base editing can produce durable and efficient changes in protein production by the liver, with a clear route to protection from heart attack. Six-month data shared by...
BioCentury | Dec 31, 2020
Distillery Therapeutics

Agonizing adiponectin receptors to treat NASH, liver fibrosis

DISEASE CATEGORY: Hepatic INDICATION: Non-alcoholic steatohepatitis (NASH); liver fibrosis An ADIPOR1 and ADIPOR2 dual agonist based on the endogenous adipocytokine adiponectin could treat NASH and liver fibrosis. Chemical synthesis of analogs of adiponectin’s globular domain yielded a peptide...
BioCentury | Dec 17, 2020
Finance

New Italian VC’s first play is Spanish biotech chasing notoriously difficult target

Recently launched European investment vehicle AurorA Science has placed its first marker on a company going after one of life sciences’ most infamous oncogene targets: MYC. AurorA Science led Barcelona-based Peptomyc S.L.’s €11.4 million ($13.8 million)...
BioCentury | Nov 19, 2020
Finance

Syncona enters kidney disease space with gene therapy newco Purespring

The launch of Purespring Therapeutics marks the next phase of Syncona’s strategy in moving gene therapy from targeting rare monogenic diseases to more complex, highly prevalent settings. On Thursday, Syncona Ltd. (LSE:SYNC) launched its sixth...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
Items per page:
1 - 10 of 1110
BioCentury | Feb 18, 2021
Management Tracks

Day One names York COO, CFO; plus moves at Coherus, Antios, ArsenalBio, Affinia, Artelo and more

After raising a $130 million series B round last week, pediatric oncology company Day One Biopharmaceuticals LLC hired Charles N. York II as COO and CFO. York was CFO and head of corporate development at...
BioCentury | Feb 12, 2021
Emerging Company Profile

With $70M A round, Takeda deal, 5AM’s Ensoma aims for accessible cell and gene therapies via empty adenoviral vectors

Launched with a $70 million series A round and a Takeda deal in hand, Ensoma is the latest company focused on broadening access to cell and gene therapies, leveraging high-capacity vectors to  develop one-time, off-the-shelf...
BioCentury | Jan 20, 2021
Finance

Rexgenero rebrands as Ikaxa, raises £40M following gene therapy deal

With an aim to bring its recently acquired synthetic gene delivery platform into the clinic, Rexgenero Ltd. has recapitalized and rebranded as cell and gene therapy company Ikaxa Ltd. The London-based biotech said undisclosed existing...
BioCentury | Jan 20, 2021
Emerging Company Profile

Aulos: Tackling the IL-2 space with computational biology

Apple Tree Partners launched Aulos into the crowded IL-2 space last week with a $40 million series A round and a computationally designed IL-2-binding antibody it thinks could have an edge in efficacy...
BioCentury | Jan 13, 2021
Deals

Boehringer accesses untouched cancer targets through Enara deal

Boehringer’s reach into the most cutting-edge science continues through its new deal with Enara to access dark antigen targets for cancer immunotherapies.  Boehringer Ingelheim GmbH teamed up with...
BioCentury | Jan 13, 2021
Product Development

Why Verve chose base editing over standard CRISPR for its lead CV candidate

Verve’s non-human primate data makes the case that base editing can produce durable and efficient changes in protein production by the liver, with a clear route to protection from heart attack. Six-month data shared by...
BioCentury | Dec 31, 2020
Distillery Therapeutics

Agonizing adiponectin receptors to treat NASH, liver fibrosis

DISEASE CATEGORY: Hepatic INDICATION: Non-alcoholic steatohepatitis (NASH); liver fibrosis An ADIPOR1 and ADIPOR2 dual agonist based on the endogenous adipocytokine adiponectin could treat NASH and liver fibrosis. Chemical synthesis of analogs of adiponectin’s globular domain yielded a peptide...
BioCentury | Dec 17, 2020
Finance

New Italian VC’s first play is Spanish biotech chasing notoriously difficult target

Recently launched European investment vehicle AurorA Science has placed its first marker on a company going after one of life sciences’ most infamous oncogene targets: MYC. AurorA Science led Barcelona-based Peptomyc S.L.’s €11.4 million ($13.8 million)...
BioCentury | Nov 19, 2020
Finance

Syncona enters kidney disease space with gene therapy newco Purespring

The launch of Purespring Therapeutics marks the next phase of Syncona’s strategy in moving gene therapy from targeting rare monogenic diseases to more complex, highly prevalent settings. On Thursday, Syncona Ltd. (LSE:SYNC) launched its sixth...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
Items per page:
1 - 10 of 1110